Form 4: Corcept Executive Executes Stock Option Exercise and Sale

Corcept Therapeutics President Sean Maduck exercised 75,000 stock options and sold 75,000 shares under a 10b5-1 trading plan.

Summary

• Sean Maduck, President of Corcept Endocrinology, exercised 75,000 stock options at a strike price of $8.27 per share.
• Following the exercise, the reporting person sold 75,000 shares of common stock in two tranches.
• The first tranche of 54,575 shares was sold at a weighted average price of $65.3711.
• The second tranche of 20,425 shares was sold at a weighted average price of $66.1599.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a routine, pre-planned insider transaction that does not reflect a change in the company's fundamental outlook.

Positives

• The executive maintains a significant remaining beneficial ownership of 29,402 shares directly, plus additional indirect holdings through trusts and LLCs.
• The transaction was pre-planned via a 10b5-1 plan, indicating a structured approach to liquidity rather than reactive selling.

Negatives

• The transaction represents a significant divestment of 75,000 shares by a key member of the leadership team.

Risks

• Future share price volatility may impact the value of remaining holdings.
• Reliance on 10b5-1 plans does not eliminate the potential for negative market perception regarding insider selling.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The transaction was conducted under a pre-established 10b5-1 plan.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for executives in the biotechnology sector to manage personal financial planning and diversify holdings while avoiding concerns regarding non-public information.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for corporate officers to execute equity sales to ensure compliance with SEC regulations.
• The scale of the sale is consistent with typical executive compensation and liquidity events for mid-cap biotech firms.

Related Party Transactions

• The reporting person holds shares through various trusts and LLCs, including the Sean and Molly Maduck Living Trust, MMM 2025, LLC, and two Grantor Retained Annuity Trusts.

Stakeholder Impact

• Shareholders should note the reduction in direct insider ownership, though the transaction was pre-planned.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Corcept Therapeutics, CORT, Insider Trading, Form 4, Stock Options, 10b5-1, Biotech